KNSA · NASDAQ
Kiniksa Pharmaceuticals International (KNSA) Stock Price & Fundamentals
Kiniksa Pharmaceuticals International (KNSA) closed at $417.72 on Oct 9, 2026, up 1.03% from the previous close of $413.45.
Share price, past year
1Y +4.54%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $417.72 |
| Sep 30, 2026 | $434.44 |
| Aug 31, 2026 | $457.96 |
| Jul 31, 2026 | $458.73 |
| Jun 30, 2026 | $453.47 |
| May 29, 2026 | $467.01 |
| Apr 30, 2026 | $455.11 |
| Mar 31, 2026 | $467.58 |
| Feb 27, 2026 | $481.06 |
| Jan 30, 2026 | $455.30 |
| Dec 31, 2025 | $419.32 |
| Nov 28, 2025 | $417.26 |
| Oct 31, 2025 | $397.10 |
Key statistics
- Market cap
- —
- P/E (TTM)
- 459.0
- EPS (TTM)
- $0.91
- Revenue (TTM)
- $754.05M
- Net income (TTM)
- $73.06M
- Shares outstanding
- —
- Dividend yield
- —
- 52-week range
- $387.66 – $483.83
Financials
Kiniksa Pharmaceuticals International reported revenue of $677.56M for fiscal 2025, up 60.09% from fiscal 2024.
Kiniksa Pharmaceuticals International earned net income of $59.01M in fiscal 2025, a net margin of 8.7%.
Fiscal 2025 revenue was the highest in the 5 years shown.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $677.56M | +60.1% | $59.01M | 8.7% | $0.75 | $136.42M |
| FY2024ended Dec 31, 2024 | $423.24M | +56.6% | −$43.19M | −10.2% | −$0.60 | $25.41M |
| FY2023ended Dec 31, 2023 | $270.26M | +22.7% | $14.08M | 5.2% | $0.20 | $13.17M |
| FY2022ended Dec 31, 2022 | $220.18M | +471.2% | $183.36M | 83.3% | $2.60 | $5.70M |
| FY2021ended Dec 31, 2021 | $38.54M | — | −$157.92M | −409.7% | −$2.30 | −$126.71M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q1 FY2026ended Mar 31, 2026 | $214.27M | $22.59M | $0.27 |
| Q4 FY2025ended Dec 31, 2025 | $202.13M | $14.20M | $0.18 |
| Q3 FY2025ended Sep 30, 2025 | $180.86M | $18.44M | $0.23 |
| Q2 FY2025ended Jun 30, 2025 | $156.80M | $17.83M | $0.23 |
| Q1 FY2025ended Mar 31, 2025 | $137.79M | $8.54M | $0.11 |
| Q4 FY2024ended Dec 31, 2024 | $122.54M | −$8.89M | −$0.11 |
| Q3 FY2024ended Sep 30, 2024 | $112.21M | −$12.69M | −$0.18 |
| Q2 FY2024ended Jun 30, 2024 | $108.63M | −$3.91M | −$0.06 |
Company profile
- Name
- Kiniksa Pharmaceuticals International, plc
- Ticker
- KNSA
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 105 Piccadilly, Second Floor, London, W1J 7NJ
- Fiscal year ends
- December
- SEC CIK
- 0001730430
Recent SEC filings
- Jul 28, 2026
- Jul 28, 2026
- May 29, 2026
- May 26, 2026
- May 1, 2026
- Apr 28, 2026
- Apr 28, 2026
- Feb 24, 2026
Frequently asked questions
What is Kiniksa Pharmaceuticals International's stock price?
Kiniksa Pharmaceuticals International (KNSA) closed at $417.72 on Oct 9, 2026, up 1.03% from the previous close of $413.45.
How much revenue does Kiniksa Pharmaceuticals International make?
Kiniksa Pharmaceuticals International reported revenue of $677.56M for fiscal 2025, up 60.09% from fiscal 2024.
What is KNSA's P/E ratio?
Kiniksa Pharmaceuticals International's price-to-earnings ratio is 459.0, based on trailing twelve-month diluted EPS of $0.91.
Does Kiniksa Pharmaceuticals International pay a dividend?
Kiniksa Pharmaceuticals International's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Kiniksa Pharmaceuticals International, plc's filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures